ANIP vs. CPRX, CNCE, PGNX, SELB, CTMX, CYTK, APLS, MDGL, ALPN, and NUVL
Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Catalyst Pharmaceuticals (CPRX), Concert Pharmaceuticals (CNCE), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB), CytomX Therapeutics (CTMX), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), and Nuvalent (NUVL). These companies are all part of the "medical" sector.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Catalyst Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Catalyst Pharmaceuticals presently has a consensus price target of $26.71, indicating a potential upside of 65.21%. ANI Pharmaceuticals has a consensus price target of $81.00, indicating a potential upside of 24.81%. Given ANI Pharmaceuticals' higher probable upside, research analysts plainly believe Catalyst Pharmaceuticals is more favorable than ANI Pharmaceuticals.
Catalyst Pharmaceuticals received 57 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 74.31% of users gave Catalyst Pharmaceuticals an outperform vote while only 64.64% of users gave ANI Pharmaceuticals an outperform vote.
In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.30 beat ANI Pharmaceuticals' score of 0.63 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Catalyst Pharmaceuticals' net margin of 6.87%. ANI Pharmaceuticals' return on equity of 25.08% beat Catalyst Pharmaceuticals' return on equity.
Catalyst Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Catalyst Pharmaceuticals beats ANI Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get ANI Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ANI Pharmaceuticals Competitors List
Related Companies and Tools
